2025年开年不到一个月,康诺亚(02162.HK)第二次宣布通过NewCo的方式达成一宗出海交易。1 月 20 日,康诺亚联合诺诚健华(688428.SH)共同宣布,两家公司的子公司及其双方的合资公司共同和一家美国公司Prolium Bioscience(下称Prolium)达成许可合作,授权Prolium开发和商业化CD20×CD3双特异性抗体ICP-B02(CM355)。根据协议,北京...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.